Cancer susceptibility gene mutations in individuals with colorectal cancer

Journal of Clinical Oncology

Volumn 35, Issue 10, 2017, Pages 1086-1095

  Yurgelun, Matthew B ^a,b,c   Kulke, Matthew H ^a,b,c   Fuchs, Charles S ^a,b,c   Allen, Brian A ^d   Uno, Hajime ^a,b   Hornick, Jason L ^b,c   Ukaegbu, Chinedu I ^a   Brais, Lauren K ^a   McNamara, Philip G ^a   Mayer, Robert J ^a,b,c   Schrag, Deborah ^a,b,c   Meyerhardt, Jeffrey A ^a,b,c   Ng, Kimmie ^a,b,c   Kidd, John ^d   Singh, Nanda ^d   Hartman, Anne Renee ^d   Wenstrup, Richard J ^d   Syngal, Sapna ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d Myriad Genetic Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA GLYCOSYLASE MUTY; PROTEIN P53; APC PROTEIN, HUMAN; CHECKPOINT KINASE 2; CHEK2 PROTEIN, HUMAN; DNA BINDING PROTEIN; DNA GLYCOSYLTRANSFERASE; EPCAM PROTEIN, HUMAN; EPITHELIAL CELL ADHESION MOLECULE; G-T MISMATCH-BINDING PROTEIN; MISMATCH REPAIR PROTEIN PMS2; MLH1 PROTEIN, HUMAN; MSH2 PROTEIN, HUMAN; MUTL PROTEIN HOMOLOG 1; NUCLEAR PROTEIN; PALB2 PROTEIN, HUMAN; PMS2 PROTEIN, HUMAN; PROTEIN MSH2; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; APC GENE; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; CDKN2A GENE; COLORECTAL CANCER; FAMILY HISTORY; FEMALE; GENE MUTATION; GERMLINE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTYH GENE; ONCOGENE; PALB2 GENE; PRIORITY JOURNAL; TP53 GENE; TUMOR SUPPRESSOR GENE; CHEMISTRY; COLORECTAL TUMOR; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION; GENETICS; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; MIDDLE AGED; PENETRANCE; VERY ELDERLY; YOUNG ADULT;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ADULT; AGED; AGED, 80 AND OVER; CHECKPOINT KINASE 2; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA GLYCOSYLASES; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; EPITHELIAL CELL ADHESION MOLECULE; FEMALE; GENES, BRCA1; GENES, BRCA2; GENES, P16; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MALE; MIDDLE AGED; MISMATCH REPAIR ENDONUCLEASE PMS2; MUTL PROTEIN HOMOLOG 1; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS; PENETRANCE; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 85016626649     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.71.0012     Document Type: Article

References (44)

1. Ward RL, Hicks S, Hawkins NJ: Populationbased molecular screening for Lynch syndrome: Implications for personalized medicine. J Clin Oncol 31:2554-2562, 2013
2. Moreira L, Balaguer F, Lindor N, et al: Identification of Lynch syndrome among patients with colorectal cancer. JAMA 308:1555-1565, 2012
3. Kastrinos F, Ojha RP, Leenen C, et al: Comparison of prediction models for lynch syndrome among individuals with colorectal cancer. J Natl Cancer Inst 108:djv308, 2015
4. Hampel H, Frankel WL, Martin E, et al: Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 26: 5783-5788, 2008
5. Hampel H, Frankel WL, Martin E, et al: Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352: 1851-1860, 2005
6. Woods MO, Younghusband HB, Parfrey PS, et al: The genetic basis of colorectal cancer in a population-based incident cohort with a high rate of familial disease. Gut 59:1369-1377, 2010
7. Grover S, Kastrinos F, Steyerberg EW, et al: Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas. JAMA 308:485-492, 2012
8. Lubbe SJ, Di Bernardo MC, Chandler IP, et al: Clinical implications of the colorectal cancer risk associated with MUTYH mutation. J Clin Oncol 27: 3975-3980, 2009
9. Bertario L, Russo A, Sala P, et al: Multiple approach to the exploration of genotype-phenotype correlations in familial adenomatous polyposis. J Clin Oncol 21:1698-1707, 2003
10. Cleary SP, Cotterchio M, Jenkins MA, et al: Germline MutY human homologue mutations and colorectal cancer: A multisite case-control study. Gastroenterology 136:1251-1260, 2009
11. Boursi B, Sella T, Liberman E, et al: The APC p. I1307K polymorphism is a significant risk factor for CRC in average risk Ashkenazi Jews. Eur J Cancer 49:3680-3685, 2013
12. Win AK, Dowty JG, Cleary SP, et al: Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer. Gastroenterology 146:1208-1211.e5, 2014
13. Yurgelun MB, Allen B, Kaldate RR, et al: Identification of a variety of mutations in cancer predisposition genes in patients with suspected Lynch syndrome. Gastroenterology 149:604-613. e20, 2015
14. Phelan CM, Iqbal J, Lynch HT, et al: Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: Results from a follow-up study. Br J Cancer 110:530-534, 2014
15. Tung N, Lin NU, Kidd J, et al: Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol 34:1460-1468, 2016
16. Guarinos C, Ju arez M, Egoavil C, et al: Prevalence and characteristics of MUTYH-associated polyposis in patients with multiple adenomatous and serrated polyps. Clin Cancer Res 20:1158-1168, 2014
17. Aime A, Coulet F, Lefevre JH, et al: Somatic c.34G.T KRAS mutation: A new prescreening test for MUTYH-associated polyposis? Cancer Genet 208:390-395, 2015
18. Judkins T, Leclair B, Bowles K, et al: Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk. BMC Cancer 15:215, 2015
19. Giardiello FM, Allen JI, Axilbund JE, et al: Guidelines on genetic evaluation and management of Lynch syndrome: A consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 147:502-526, 2014
20. Syngal S, Brand RE, Church JM, et al: ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 110:223-262, 2015; quiz 263
21. NCCN Clinical Practice Guidelines in Oncology: Genetic/familial high-risk assessment: Colorectal. Version 2, 2016. http://www.nccn.org/professionals/physician-gls/pdf/genetics-colon.pdf
22. NCCN Clinical Practice Guidelines in Oncology: Genetic/familial high-risk assessment: Breast and ovarian. Version 1, 2017. http://www.nccn.org/professionals/physician-gls/pdf/genetics-screening. pdf
23. Antoniou AC, Casadei S, Heikkinen T, et al: Breast-cancer risk in families with mutations in PALB2. N Engl J Med 371:497-506, 2014
24. Malkin D: Li-Fraumeni syndrome. Genes Cancer 2:475-484, 2011
25. Bishop DT, Demenais F, Goldstein AM, et al: Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 94: 894-903, 2002
26. Easton DF, Pharoah PD, Antoniou AC, et al: Gene-panel sequencing and the prediction of breastcancer risk. N Engl J Med 372:2243-2257, 2015
27. Ramus SJ, Song H, Dicks E, et al: Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer. J Natl Cancer Inst 107:djv214, 2015
28. Robson ME, Bradbury AR, Arun B, et al: American Society of Clinical Oncology policy statement update: Genetic and genomic testing for cancer susceptibility. J Clin Oncol 33:3660-3667, 2015
29. McClain MR, Palomaki GE, Nathanson KL, et al: Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: Public health implications. Genet Med 7: 28-33, 2005
30. Maxwell KN, Domchek SM, Nathanson KL, et al: Population frequency of germline BRCA1/2 mutations. J Clin Oncol 34:4183-4185, 2016
31. Niell BL, Rennert G, Bonner JD, et al: BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. J Natl Cancer Inst 96:15-21, 2004
32. Kirchhoff T, Satagopan JM, Kauff ND, et al: Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. J Natl Cancer Inst 96:68-70, 2004
33. Kadouri L, Hubert A, Rotenberg Y, et al: Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations. J Med Genet 44:467-471, 2007
34. Suchy J, Cybulski C, Gorski B, et al: BRCA1 mutations and colorectal cancer in Poland. Fam Cancer 9:541-544, 2010
35. Garre P, Martin L, Sanz J, et al: BRCA2 gene: A candidate for clinical testing in familial colorectal cancer type X. Clin Genet 87:582-587, 2015
36. Tung N, Domchek SM, Stadler Z, et al: Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol 13:581-588, 2016
37. Wood ME, Kadlubek P, Pham TH, et al: Quality of cancer family history and referral for genetic counseling and testing among oncology practices: A pilot test of quality measures as part of the American Society of Clinical Oncology Quality Oncology Practice Initiative. J Clin Oncol 32:824-829, 2014
38. Grover S, Stoffel EM, Bussone L, et al: Physician assessment of family cancer history and referral for genetic evaluation in colorectal cancer patients. Clin Gastroenterol Hepatol 2:813-819, 2004
39. Gallego CJ, Shirts BH, Bennette CS, et al: Next-generation sequencing panels for the diagnosis of colorectal cancer and polyposis syndromes: A cost-effectiveness analysis. J Clin Oncol 33: 2084-2091, 2015
40. Le DT, Uram JN, Wang H, et al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509-2520, 2015
41. Mateo J, Carreira S, Sandhu S, et al: DNArepair defects and olaparib in metastatic prostate cancer. N Engl J Med 373:1697-1708, 2015
42. Kaufman B, Shapira-Frommer R, Schmutzler RK, et al: Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 33:244-250, 2015
43. Abdelsattar ZM, Wong SL, Regenbogen SE, et al: Reply to percentage of colorectal cancer diagnoses in adults aged younger than 50 years. Cancer 122:1463-1464, 2016
44. Bibbins-Domingo K, Grossman DC, Curry SJ, et al: Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA 315:2564-2575, 2016